Our findings help to elucidate the mechanism landscape for USP3 regarding its roles in regulating GC progression and supporting molecules, including USP3, COL9A3 and COL6A5 as the underlying targets for GC management in clinical settings. The gene discussed is COL6A5; the disease is gastric cancer.